Literature DB >> 3521830

Chondrosarcoma with additional mesenchymal component (dedifferentiated chondrosarcoma). II. An immunohistochemical and electron microscopic study.

B Têtu, N G Ordóñez, A G Ayala, B Mackay.   

Abstract

Light microscopic, immunocytochemical and ultrastructural studies were performed on chondrosarcomas which contained a second, noncartilagenous mesenchymal component. Attention was focused on the nonchondroid portion of each tumor in an attempt to elucidate the histogenesis of this mixed variant of chondrosarcoma. The immunoreactivity of 20 tumors was studied using antisera for S-100 protein, alpha-1-antitrypsin, alpha-1-antichymotrypsin, smooth muscle myosin, desmin, and myoglobin. Cells of the nonchondroid portion stained for alpha-1-antichymotrypsin in 12 of 20 cases, and these were predominantly tumors that had been classified as fibrosarcoma or malignant fibrous histiocytoma by conventional light microscopic study. Staining for S-100 protein was consistently negative, whereas the chondrosarcoma component stained in 14 cases. Six tumors stained for desmin, and four of the six were positive for myoglobin and two for smooth muscle myosin; in four, a rhabdomyosarcomatous component was identified in the hematoxylin and eosin-stained sections. Electron microscopic study was performed on ten tumors and there was a good correlation between the immunohistochemical and ultrastructural findings. Three of the ten were pure rhabdomyosarcomas while the others displayed a range of ultrastructural appearances that can be seen in fibrosarcomas and malignant fibrous histiocytomas. The findings from this study support the view that the tumors are formed by the synchronous differentiation of two separate clones of cells.

Entities:  

Mesh:

Year:  1986        PMID: 3521830     DOI: 10.1002/1097-0142(19860715)58:2<287::aid-cncr2820580214>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Pathobiology of selected tumors of the base of the skull.

Authors:  L Barnes
Journal:  Skull Base Surg       Date:  1991

2.  Case report 459: Fibrosarcomatous dedifferentiation of chondrosarcoma of the tibia.

Authors:  J K Lee; L Yao; C T Phelps; V A Pilon; C R Wirth
Journal:  Skeletal Radiol       Date:  1988       Impact factor: 2.199

3.  Dedifferentiated chondrosarcoma--a fatal disease.

Authors:  J Bruns; W Fiedler; M Werner; G Delling
Journal:  J Cancer Res Clin Oncol       Date:  2005-03-23       Impact factor: 4.553

4.  Primary extraskeletal mesenchymal chondrosarcoma of the lid.

Authors:  J M Rohrbach; K P Steuhl; H Pressler; E Kaiserling; G Schaumburg-Lever; H G Scheel-Walter
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

Review 5.  Primary rhabdomyosarcoma of the iliac bone in an adult: a case mimicking fibrosarcoma.

Authors:  Y Oda; M Tsuneyoshi; H Hashimoto; T Iwashita; M Ushijima; S Masuda; Y Iwamoto; Y Sugioka
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

6.  Retroperitoneal mesenchymal chondrosarcoma mimicking a large retroperitoneal sacral schwannoma.

Authors:  Giancarlo D'Andrea; Emanuela Caroli; Michela Giuli Capponi; Francesco Scicchitano; Mattia Falchetto Osti; Carlo Bellotti; Luigi Ferrante
Journal:  Neurosurg Rev       Date:  2007-10-03       Impact factor: 3.042

7.  Dedifferentiated chondrosarcoma of bone. An immunohistochemical and lectin-histochemical study.

Authors:  M R Wick; G P Siegal; S E Mills; R C Thompson; D Sawhney; R E Fechner
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

8.  Dedifferentiated chondrosarcoma.

Authors:  M Mercuri; P Picci; L Campanacci; E Rulli
Journal:  Skeletal Radiol       Date:  1995-08       Impact factor: 2.199

9.  Targeted next-generation sequencing of dedifferentiated chondrosarcoma in the skull base reveals combined TP53 and PTEN mutations with increased proliferation index, an implication for pathogenesis.

Authors:  Lu Gao; Xiafei Hong; Xiaopeng Guo; Dengfeng Cao; Xiaohuan Gao; Thomas F DeLaney; Xinqi Gong; Rongrong Chen; Jianjiao Ni; Yong Yao; Renzhi Wang; Xi Chen; Pangzehuan Tian; Bing Xing
Journal:  Oncotarget       Date:  2016-07-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.